After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
This is the first update to the original CTS communication distributed on July 6th. As previously co...